Levaquin Leva-Pak
Brand names,
Levaquin Leva-Pak
Analogs
Levaquin Leva-Pak
Brand Names Mixture
Levaquin Leva-Pak
Chemical_Formula
C36H42F2N6O9
Levaquin Leva-Pak
RX_link
http://www.rxlist.com/cgi/generic2/quixin.htm
Levaquin Leva-Pak
fda sheet
Levaquin Leva-Pak
msds (material safety sheet)
Levaquin Leva-Pak
Synthesis Reference
Mitscher, Lester A. et al.; J.Med.Chem.; 30; 12; 2283-2286(1987)
Levaquin Leva-Pak
Molecular Weight
740.751 g/mol
Levaquin Leva-Pak
Melting Point
No information avaliable
Levaquin Leva-Pak
H2O Solubility
Insoluble
Levaquin Leva-Pak
State
Solid
Levaquin Leva-Pak
LogP
1.268
Levaquin Leva-Pak
Dosage Forms
Tablet; Liquid; Solution
Levaquin Leva-Pak
Indication
For the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species, Staphylococus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus (Groups C/F/G), Viridans group streptococci, Acinetobacter lwoffii, Haemophilus influenzae, Serratia marcescens.
Levaquin Leva-Pak
Pharmacology
Levofloxacin, a fluoroquinolone antiinfective, is the optically active L-isomer of ofloxacin. Levofloxacin is used to treat bacterial conjunctivitis, sinusitis, chronic bronchitis, community-acquired pneumonia and pneumonia caused by penicillin-resistant strains of Streptococcus pneumoniae, skin and skin structure infections, complicated urinary tract infections and acute pyelonephritis.
Levaquin Leva-Pak
Absorption
Absorption of ofloxacin after single or multiple doses of 200 to 400 mg is predictable, and the amount of drug absorbed increases proportionately with the dose.
Levaquin Leva-Pak
side effects and Toxicity
Side effects include disorientation, dizziness, drowsiness, hot and cold flashes, nausea, slurring of speech, swelling and numbness in the face
Levaquin Leva-Pak
Patient Information
PATIENT INFORMATION
While taking ofloxacin patient should be advised to:
� to drink fluids liberally;
� that mineral supplements, vitamins with iron or minerals, calcium- , aluminum-, or magnesium-based antacids, sucralfate or Videx�, (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution should not be taken within the two-hour period before or within the two-hour period after taking ofloxacin;
� that ofloxacin can be taken without regard to meals;
� that ofloxacin may cause neurologic adverse effects (e. g. , dizziness, lightheadedness) and that patients should know how they react to ofloxacin before they operate an automobile or machinery or engage in activities requiring mental alertness and coordination;
� to discontinue treatment and inform their physician if they experience pain, inflammation, or rupture of a tendon, and to rest and refrain from exercise until the diagnosis of tendinitis or tendon rupture has been confidently excluded;
� that ofloxacin may be associated with hypersensitivity reactions, even following the first dose, to discontinue the drug at the first sign of a skin rash, hives or other skin reactions, a rapid heartbeat, difficulty in swallowing or breathing, any swelling suggesting angioedema (e. g. , swelling of the lips, tongue, face; tightness of the throat, hoarseness), or any other symptom of an allergic reaction
� to avoid excessive sunlight or artificial ultraviolet light while receiving ofloxacin and to discontinue therapy if phototoxicity (e. g. , skin eruption) occurs;
� that if they are diabetic and are being treated with insulin or an oral hypoglycemic drug, to discontinue ofloxacin immediately if a hypoglycemic reaction occurs and consult a physician;
� that convulsions have been reported in patients taking quinolones, including ofloxacin, and to notify their physician before taking this drug if there is a history of this condition.
Levaquin Leva-Pak
Organisms Affected
Enteric bacteria and other eubacteria